BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (Nasdaq: ARRY) today announced that data from a Phase 1 trial of AZD6244 (ARRY-142886), a novel MEK inhibitor, will be presented at the 18th Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held from November 7-10, 2006 in Prague, Czech Republic.
